Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand

被引：61

作者：

Berman, PW ^{[1
]}

Huang, W ^{[1
]}

Riddle, L ^{[1
]}

Gray, AM ^{[1
]}

Wrin, T ^{[1
]}

Vennari, J ^{[1
]}

Johnson, A ^{[1
]}

Klaussen, M ^{[1
]}

Prashad, H ^{[1
]}

Köhne, C ^{[1
]}

DeWit, C ^{[1
]}

Gregory, TJ ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

VIROLOGY | 1999年 / 265卷 / 01期

关键词：

HIV; vaccine; CCR5; CXCR4; antibodies; neutralization;

D O I：

10.1006/viro.1999.0031

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Recombinant envelope glycoproteins prepared from a subtype a (MN) strain and a subtype E (CM244) strain of HIV-1 were combined to create a bivalent vaccine (B/E) effective against viruses circulating in the United States and Asia. Combining the two antigens resulted in formulations that increased the breadth and potency of the inter-subtype neutralizing response. Antibodies to the bivalent Vaccine formulation neutralized viruses possessing diverse phenotypes, including syncytia-inducing and non-syncytia-inducing primary isolates, viruses using either the CCR5 or the CXCR4 chemokine receptors, and Viruses differing in their sensitivity to soluble CD4. These studies demonstrate for the first time that the magnitude and quality of the immune response to HIV-1 can be improved by combining recombinant envelope glycoproteins from different genetic subtypes, (C) 1999 Academic Press.

引用

页码：1 / 9

页数：9

共 45 条

[41] CROSS-CLADE NEUTRALIZATION OF PRIMARY ISOLATES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY HUMAN MONOCLONAL-ANTIBODIES AND TETRAMERIC CD4-IGG [J].